ArticleScience advances2022
When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 93 citations in OpenAlex.
- Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy.Pharmaceutical science advances · 2026Review
- Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations.Inflammopharmacology · 2026Review
- RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.Science advances · 2026Article
- Macrophages tune NK cell IFNγ production through direct lipid transfer.Nature communications · 2026Article
- CYBRD1 is transcriptionally regulated by RUNX1 and mediates JAK2/STAT3 signaling activation during ovarian cancer progression.Oncogenesis · 2026Article
- Immune surveillance interrupted: how cancer exploits trogocytosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Trogocytosis in cancer immunity and cellular immunotherapy: mechanisms, therapeutic challenges, and translational opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Programmable macromolecule delivery via engineered trogocytosis.Nature cell biology · 2026Article
- Trogocytosis and Allergy.Cells · 2026Review
- Density of tertiary lymphoid structures predict clinical outcome in hepatoblastoma.Pediatric research · 2026Article
- Programmed cell death-1: from a T-cell immune checkpoint to a regulator of Natural Killer cell biology.Frontiers in cell and developmental biology · 2026Review
- Metabolic Reprogramming ofCancer communications (London, England) · 2026Article
- Review
- PD-1 Expression Promotes Immune Evasion in B-ALL.Hematology reports · 2025Article
- PD-1Journal of experimental & clinical cancer research : CR · 2025Article
- Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.Journal of experimental & clinical cancer research : CR · 2025Review
- Molecular Dynamics of Trogocytosis and Other Contact-Dependent Cell Trafficking Mechanisms in Tumor Pathogenesis.Cancers · 2025Review
- Masters of adaptation: How cancer and immune cell plasticity mediates tumor progression.PLoS biology · 2025Review
- LAG3 Marks Activated but Hyporesponsive NK Cells.European journal of immunology · 2025Article
- Natural killer cells: the immune frontline against circulating tumor cells.Journal of experimental & clinical cancer research : CR · 2025Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 10 institutions in 4 countries.
Mohamed S HasimCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-0275-3378
Marie MarotelCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-1618-7602
Jonathan J HodginsCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-0390-5599
Elisabetta VulpisDepartment of Molecular Medicine, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci-Bolognetti, Rome, Italy.
Olivia J MakinsonCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-4570-8534
Sara AsifCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Han-Yu ShihNeuro-Immune Regulome Unit, National Eye Institute, NIH, Bethesda, MD, USA.ORCID 0000-0002-7525-5433
Amit K ScheerDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0001-5689-0055
Olivia MacMillanCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0003-0518-3101
Felipe G AlonsoCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-9900-0013
Kelly P BurkeDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2187-0147
David P CookCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0001-7639-6724
Rui LiDepartment of Medicine, McGill University, Montréal, QC, Canada.ORCID 0000-0002-4803-5339
Maria Teresa PetrucciDepartment of Cellular Biotechnology and Hematology, "Sapienza" University of Rome, Rome, Italy.ORCID 0000-0003-0688-4882
Angela SantoniDepartment of Molecular Medicine, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci-Bolognetti, Rome, Italy.
Padraic G FallonSchool of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.ORCID 0000-0002-8401-7293
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9736-2109
Giuseppe SciumèDepartment of Molecular Medicine, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci-Bolognetti, Rome, Italy.
André VeilletteDepartment of Medicine, McGill University, Montréal, QC, Canada.ORCID 0000-0003-1159-4345
Alessandra ZingoniDepartment of Molecular Medicine, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci-Bolognetti, Rome, Italy.
Douglas A GrayCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Arleigh McCurdyCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0002-8809-4368
Michele ArdolinoCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0003-4114-0985
University of Ottawa · CAIstituto Pasteur · ITMontreal Clinical Research Institute · CAOttawa Hospital · CABrigham and Women's Hospital · USHarvard University · USIstituto Neurologico Mediterraneo · ITNational Eye Institute · USSapienza University of Rome · ITTrinity College Dublin · IE
Funding
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5MGenomic regulation of immune response in neurodegeneration in miceZIAEY000569 · NEI · NATIONAL EYE INSTITUTE · PI SHIH, HAN-YU · 2020 to 2025
$10.0MIntramural NIH HHS ZIA EY000569NIAID NIH HHS P01 AI056299
Abstract
Trogocytosis modulates immune responses, with still unclear underlying molecular mechanisms. Using leukemia mouse models, we found that lymphocytes perform trogocytosis at high rates with tumor cells. While performing trogocytosis, both Natural Killer (NK) and CD8
Indexed as
LeukemiaNeoplasmsAnimalsCD8-Positive T-LymphocytesHumansKiller Cells, NaturalMiceProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.